Published in Langenbecks Arch Surg on February 16, 2007
Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis (2007) 1.23
Newly discovered angiogenesis inhibitors and their mechanisms of action. Acta Pharmacol Sin (2012) 0.91
Lymphangiogenic and angiogenic microvessel density in human primary sporadic colorectal carcinoma. World J Gastroenterol (2008) 0.90
A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells. Int J Mol Sci (2014) 0.85
Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Res (2008) 0.85
Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol (2008) 0.84
Mesenchymal stem cells with rhBMP-2 inhibits the growth of canine osteosarcoma cells. BMC Vet Res (2012) 0.82
Vascular disrupting agent drug classes differ in effects on the cytoskeleton. PLoS One (2012) 0.81
Early incorporated endothelial cells as origin of metastatic tumor vasculogenesis. Clin Exp Metastasis (2009) 0.80
Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors. Oncol Rep (2015) 0.80
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs (2013) 0.79
Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells. J Biomed Biotechnol (2010) 0.77
Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A. Invest New Drugs (2015) 0.76
Structural Mechanisms and Drug Discovery Prospects of Rho GTPases. Cells (2016) 0.76
Thalidomide and irradiation combination therapy increases substance P levels in vitro. Exp Ther Med (2011) 0.76
Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game. PLoS One (2017) 0.75
Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential. Sci Rep (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 2.78
Cancer without disease. Nature (2004) 2.65
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer (2006) 2.20
Involvement of platelets in tumour angiogenesis? Lancet (1998) 2.03
Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res (2006) 1.93
Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol (1999) 1.88
The hemostatic system as a regulator of angiogenesis. J Biol Chem (2000) 1.76
Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol (2005) 1.52
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol (2006) 1.41
Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis (2002) 1.40
Molecular basis of angiogenesis and cancer. Oncogene (2003) 1.38
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res (2006) 1.16
Cilengitide Merck. Curr Opin Investig Drugs (2003) 1.14
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res (1999) 1.12
The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) (2001) 1.12
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res (2003) 1.09
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol (2003) 1.07
Sorafenib. Curr Opin Oncol (2006) 0.99
Clinical implications of antiangiogenic therapies. Oncology (Williston Park) (2005) 0.95
Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis (2004) 0.93
Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) (2006) 0.91
Vascular endothelial growth factor and angiopoietins regulate sinusoidal regeneration and remodeling after partial hepatectomy in rats. World J Gastroenterol (2005) 0.89
Neoadjuvant therapy with bevacizumab. J Clin Oncol (2006) 0.82
The role of the angiopoietins in tumour angiogenesis. Growth Factors (2004) 0.76
Vascular normalization: study examines how antiangiogenesis therapies work. J Natl Cancer Inst (2005) 0.76
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis. Eur J Med Res (2009) 2.10
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int (2007) 2.10
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int (2007) 1.87
Blumgart anastomosis for pancreaticojejunostomy minimizes severe complications after pancreatic head resection. Br J Surg (2009) 1.71
Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther (2008) 1.66
[Operative techniques and outcomes in metabolic surgery: sleeve gastrectomy]. Zentralbl Chir (2009) 1.54
Techniques and results of laparoscopic antireflux surgery in Germany. Surg Endosc (2005) 1.49
Rifampin and Triclosan but not silver is effective in preventing bacterial infection of vascular dacron graft material. Eur J Vasc Endovasc Surg (2003) 1.44
[Cyberknife surgery with a radio-scalpel: a new treatment option for patients with unresectable metastases]. Zentralbl Chir (2010) 1.41
[Abdominal organ retrieval: strategies to improve quality]. Chirurg (2013) 1.38
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm (2001) 1.21
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene (2008) 1.19
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res (2000) 1.17
17 beta-Estradiol normalizes immune responses in ovariectomized females after trauma-hemorrhage. Am J Physiol Cell Physiol (2001) 1.16
Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients. Eur J Surg Oncol (2005) 1.11
Effect of combining nicotinamide as a PARS-inhibitor with selective iNOS blockade during porcine endotoxemia. Intensive Care Med (2003) 1.10
Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis (2007) 1.09
Acute pneumatosis cystoides intestinalis following allogeneic transplantation -- the surgeon's dilemma. Bone Marrow Transplant (2002) 1.09
[Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol (2011) 1.07
Transoral diverticulostomy with a modified Endo-Gia stapler: results after 4 years of experience. Surg Endosc (2006) 1.07
[Primary midline closure after excision of a pilonidal sinus is associated with a high recurrence rate]. Chirurg (2003) 1.05
Testosterone: the crucial hormone responsible for depressing myocardial function in males after trauma-hemorrhage. Ann Surg (1998) 1.05
Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. Shock (1997) 1.04
Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene (2000) 0.98
Do female sex steroids adversely or beneficially affect the depressed immune responses in males after trauma-hemorrhage? Arch Surg (2000) 0.97
Long-term results after surgical treatment of nonparasitic hepatic cysts. Am J Surg (2010) 0.95
Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. Inflamm Bowel Dis (2004) 0.95
Surgical management of splenic echinococcal disease. Eur J Med Res (2009) 0.95
Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif (2002) 0.94
Hepatic progenitor cells from adult human livers for cell transplantation. Gut (2008) 0.93
Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma. Histopathology (2005) 0.93
Laparoscopic mesh repair of incisional hernia: an alternative to the conventional open repair? Hernia (2007) 0.92
Immune dysfunction following trauma-haemorrhage: influence of gender and age. Cytokine (2000) 0.91
Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine (1999) 0.91
Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia (2001) 0.90
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut (2008) 0.89
Laparoscopic management of a small bowel perforation caused by a toothpick. Surg Endosc (2004) 0.89
Acute ischemia of the upper extremity: long-term results following thrombembolectomy with the Fogarty catheter. Langenbecks Arch Surg (2001) 0.88
Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther (2007) 0.87
[Economic consequences of complications in abdominal and thoracic surgery in the German DRG payment system]. Zentralbl Chir (2010) 0.87
Treatment of human mesenchymal stem cells with pulsed low intensity ultrasound enhances the chondrogenic phenotype in vitro. Biorheology (2006) 0.86
Leukoencephalopathy and chronic pancreatitis as concomitant manifestations of systemic lupus erythematosus related to anticardiolipin antibodies. Rheumatol Int (2003) 0.86
Surgery in immunocompromised patients. Br J Surg (2008) 0.86
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther (2006) 0.85
[Acute abdominal pain in the emergency department - a clinical algorithm for adult patients]. Zentralbl Chir (2011) 0.85
Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med (2007) 0.85
The dark side of the moon: impact of moon phases on long-term survival, mortality and morbidity of surgery for lung cancer. Eur J Med Res (2009) 0.85
Nutritional screening for risk prediction in patients scheduled for abdominal operations. Br J Surg (2012) 0.84
FTY720 inhibits tumor growth and angiogenesis. Transplant Proc (2005) 0.83
Reversal of sexual dimorphism in splenic T lymphocyte responses after trauma-hemorrhage with aging. Am J Physiol Cell Physiol (2000) 0.83
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. J Cancer Res Clin Oncol (2013) 0.82
Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir (2003) 0.82
[Impact of systematic lymph node dissection in the resection of pulmonary metastases of solid extrapulmonary tumours]. Zentralbl Chir (2010) 0.81
Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. Am J Physiol Cell Physiol (2000) 0.81
Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther (2002) 0.81
The University of Munich lung cancer group database: design, profile of cohort and outcome analysis. Eur J Med Res (2007) 0.81
A prospective clinical feasibility study for multimodal "fast track" rehabilitation in elective pancreatic cancer surgery. Rozhl Chir (2006) 0.81
[Usage of marginal organs for liver transplantation: a way around the critical organ shortage?]. Zentralbl Chir (2009) 0.81
Passion and commensurability: both are needed for a concurrence of surgery and research. Langenbecks Arch Surg (2013) 0.81
Endoluminal vacuum therapy for the treatment of anastomotic leakage after anterior rectal resection. Rozhl Chir (2008) 0.81
Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin. Target Oncol (2013) 0.80
Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol (2005) 0.80
Severe hypoxemia in the absence of blood loss causes a gender dimorphic immune response. Am J Physiol Cell Physiol (2000) 0.80
Do different rates of fluid resuscitation adversely or beneficially influence immune responses after trauma-hemorrhage? J Trauma (1999) 0.80
Castration prevents suppression of MHC class II (Ia) expression on macrophages after trauma-hemorrhage. J Appl Physiol (1985) (2006) 0.80
[Significance of multiple organ failure for the prognosis of surgical intensive care patients]. Dtsch Med Wochenschr (2006) 0.79
[Diagnosis and multimodal therapy for hepatocellular carcinoma]. Z Gastroenterol (2010) 0.79
Differences in the expression of LPS-receptors are not responsible for the sex-specific immune response after trauma and hemorrhagic shock. Cell Immunol (2004) 0.79
[Economic aspects of intensive care medicine--cost and reimbursement according to diagnosis related grouping]. Zentralbl Chir (2004) 0.79
Cyclosporine: 20 years of experience at the University of Munich. Transplant Proc (2004) 0.78
The acute phase response following implantation of triclosan-bonded vascular prostheses. Clin Exp Med (2001) 0.78
Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbecks Arch Surg (2012) 0.78
[Learning from aviation - how to increase patient safety in surgery]. Zentralbl Chir (2011) 0.78
[Surgical treatment of pulmonary metastases from renal cancer]. Urologe A (2003) 0.77
[Zenker's diverticulum treated by transoral diverticulostomy: technique and results]. Zentralbl Chir (2007) 0.77
[Dissection techniques in liver surgery]. Chirurg (2001) 0.77
Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo. Curr Cancer Drug Targets (2010) 0.77